Abstract
Pre-clinical research and case reports have linked cannabis use to myocardial infarction (MI) since the 1970s. The association with MI may be specific to certain types and patterns of cannabis use as well as certain consumer characteristics; however, due to limited data availability, meta-analyses examining the association between cannabis use and MI typically report only broad binary categorisations of use vs. no use. Robust prospective studies that capture the complexities of consumption patterns are required to inform causal inferences. In the meantime, clinicians should be aware of the potential increased risk of myocardial infarction in young healthy patients presenting with chest pain and a recent history of cannabis use. Accurate assessment and documentation of recent cannabis use is also essential to improve future research and identify and monitor interactions with cardiovascular medications.